权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Dana Farber/Harvard Cancer Center SPORE in Lung Cancer

Dana Farber/哈佛大学癌症中心 SPORE 在肺癌中的应用

基本信息

批准号：
10673920
负责人：
David A Barbie
金额：
$ 218.92万
依托单位：
DANA-FARBER CANCER INST
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-08-01 至 2027-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10673920
关键词：
Acceleration Adaptive Immune System Award Basic Science Biology Boston Cancer Center Cancer Model Cancer Patient Cancer Vaccines Cells Cessation of life Clinic Clinical Clinical Trials Collaborations Combined Modality Therapy Community Hospitals Couples Dana-Farber Cancer Institute Development Disease Drug Tolerance Enrollment Epidemiology Epidermal Growth Factor Receptor Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Fostering Foundations Funding General Hospitals Generations Geography Goals Grant Hospitals Immune Evasion Immunotherapy Individual Infrastructure Innate Immune System Institution Israel Journals Lung Lung Adenocarcinoma Malignant Neoplasms Malignant neoplasm of lung Massachusetts Measures Medical Medical center Mutation Natural Immunity Non-Small-Cell Lung Carcinoma Oncogenes Outcome Patients Pediatric Hospitals Productivity Protocols documentation Public Health Schools Publications Research Research Personnel Resistance SMARCA4 gene Sampling Signal Transduction Site Specialized Program of Research Excellence Talents Teaching Hospitals Therapeutic Therapeutic Studies Time Translating Translations Tumor Immunity Tyrosine Kinase Inhibitor United States National Institutes of Health Vaccines Woman Work adaptive immunity biomarker driven cancer clinical trial cancer immunotherapy career cost design diversity and equity effective therapy immune checkpoint blockade improved inhibitor innovation inter-institutional lung cancer screening medical schools member mouse model mutant next generation novel marker overexpression patient subsets prevent programmed cell death protein 1 programs replication stress senescence synergism targeted treatment translational approach translational goal translational scientist tumor DNA tumor immunology

项目摘要

PROJECT SUMMARY This application is a resubmission of a Specialized Program of Research Excellence (SPORE) in Lung Cancer originating from the Lung Cancer Program of the Dana-Farber/Harvard Cancer Center (DF/HCC). The DF/HCC SPORE in Lung Cancer includes researchers from multiple Harvard-affiliated hospitals including the Dana- Farber Cancer Institute (DFCI), Massachusetts General Hospital (MGH), Beth Israel Deaconess Medical Center (BIDMC), Brigham and Women’s Hospital (BWH), and Boston Children’s Hospital (BCH), as well as Harvard Medical School (HMS) and Harvard T.H. Chan School of Public Health (HSPH). Previously, the DF/HCC Lung Cancer Program was funded by a Lung Cancer SPORE in 2002. This was followed by a successful renewal application in 2007 and a no-cost extension from 2013-2015. That period of time was accompanied by remarkable productivity by our investigators, including the initial description of epidermal growth factor receptor (EGFR) mutations by investigators at both MGH and DFCI, identification and development of 3rd generation EGFR tyrosine kinase inhibitors (TKIs) which are now in widespread clinical use, and rapid translation of effective ALK/ROS targeted therapies, among other accomplishments. However, despite the immense positive impact of targeted therapies, they have failed to cure advanced lung adenocarcinoma. Over the past 6 years since our prior SPORE ended, the DF/HCC lung program has evolved and grown ever more collaborative. We have maintained a developmental research program to support a new cadre of investigators, who have built strong additional arenas of expertise that add to our longstanding tradition of targeted therapy research in lung cancer, including innate and adaptive immunity, SCLC biology, circulating tumor DNA, and lung cancer screening. The DF/HCC Lung Cancer Program thus seeks SPORE funding to enable integrated teams that capitalize on the strengths of these new and established investigators to achieve our common goal of eliminating lung cancer deaths. The overarching goals of this SPORE are to: A) Design immunologic therapies that harness both the innate and adaptive immune systems to overcome ALK inhibitor resistance and enhance efficacy of PD-1 immune checkpoint blockade in non-small cell lung cancer (NSCLC) (Projects 1 and 2); B) Develop innovative approaches to EGFR and ALK-driven lung cancer with potential to improve long term survival via cancer vaccines or elimination of drug tolerant persister (DTP) cells or cancer vaccines (Projects 1 and 3); C) Co-opt vulnerabilities such as replication stress in SMARCA4 mutant NSCLC or a senescence program in EGFR TKI DTPs (Projects 2 and 3); D) Foster inter-institutional collaboration, including exchange of lung cancer models and patient samples (all Projects); and E) Continue to support and develop the next generation of lung cancer translational scientists from our talented group of fellows and early career investigators, with an emphasis on increasing diversity and equity.

项目总结